Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Ovarian Neoplasms

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 76 articles:
HTML format

Single Articles

    January 2023
  1. YOSHIDA-COURT K, Karpinets TV, Mitra A, Solley TN, et al
    Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
    PLoS One. 2023;18:e0279590.
    PubMed     Abstract available

  2. HOSSAIN MA, Sohel M, Rahman MH, Hasan MI, et al
    Bioinformatics and In silico approaches to identify novel biomarkers and key pathways for cancers that are linked to the progression of female infertility: A comprehensive approach for drug discovery.
    PLoS One. 2023;18:e0265746.
    PubMed     Abstract available

  3. CARMICHAEL MM, Alchaar I, Davis KA, Krevosky MK, et al
    The small heat shock protein alphaB-Crystallin protects versus withaferin A-induced apoptosis and confers a more metastatic phenotype in cisplatin-resistant ovarian cancer cells.
    PLoS One. 2023;18:e0281009.
    PubMed     Abstract available

  4. ENGEVIK KA, Engevik MA, Engevik AC
    Bioinformatics reveal elevated levels of Myosin Vb in uterine corpus endometrial carcinoma patients which correlates to increased cell metabolism and poor prognosis.
    PLoS One. 2023;18:e0280428.
    PubMed     Abstract available

  5. JANG YS, Kim TW, Ryu JS, Kong HJ, et al
    Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells.
    PLoS One. 2023;18:e0277285.
    PubMed     Abstract available

  6. HAWARDEN A, Price M, Russell B, Wilson G, et al
    A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer.
    PLoS One. 2023;18:e0281798.
    PubMed     Abstract available

  7. JLASSI A, Manai M, Morjen M, Sahraoui G, et al
    VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
    PLoS One. 2023;18:e0278849.
    PubMed     Abstract available

  8. EBRING C, Marlin R, Macni J, Vallard A, et al
    Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique.
    PLoS One. 2023;18:e0278757.
    PubMed     Abstract available

  9. NUNES PEREIRA P, Francoise Derchain S, Yoshida A, Hoelz de Oliveira Barros R, et al
    Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as add-on tools to ultrasound for the differentiation of ovarian from non-ovarian pelvic masses.
    PLoS One. 2023;18:e0283212.
    PubMed     Abstract available

  10. GOLDSBURY DE, Vassallo A, Weber MF, Steinberg J, et al
    Health services costs for ovarian cancer in Australia: Estimates from the 45 and Up Study.
    PLoS One. 2023;18:e0282851.
    PubMed     Abstract available

  11. KIM NK, Suh DH, Kim K, Kim YB, et al
    Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes.
    PLoS One. 2023;18:e0284753.
    PubMed     Abstract available

  12. LOPACINSKA-JORGENSEN J, Petersen PHD, Oliveira DVNP, Hogdall CK, et al
    Strategies for data normalization and missing data imputation and consequences for potential diagnostic microRNA biomarkers in epithelial ovarian cancer.
    PLoS One. 2023;18:e0282576.
    PubMed     Abstract available

  13. Expression of Concern: Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2023;18:e0285545.

  14. WU X, Lu W, Jiang C, Zhang D, et al
    Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    PLoS One. 2023;18:e0284825.
    PubMed     Abstract available

  15. ANCHOORI RK, Anchoori V, Lam B, Tseng SH, et al
    Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.
    PLoS One. 2023;18:e0285221.
    PubMed     Abstract available

  16. LIU H, Ma S, Chen X, Wu H, et al
    Diagnostic accuracy of the Copenhagen Index in ovarian malignancy: A meta-analysis.
    PLoS One. 2023;18:e0286650.
    PubMed     Abstract available

  17. CHEN B, Lu X, Zhou Q, Chen Q, et al
    PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
    PLoS One. 2023;18:e0290031.
    PubMed     Abstract available

  18. MOATAMED NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, et al
    Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers.
    PLoS One. 2023;18:e0291361.
    PubMed     Abstract available

    January 2022
  19. SENGUPTA D, Ali SN, Bhattacharya A, Mustafi J, et al
    A deep hybrid learning pipeline for accurate diagnosis of ovarian cancer based on nuclear morphology.
    PLoS One. 2022;17:e0261181.
    PubMed     Abstract available

  20. HEITZ F, Lakis S, Harter P, Heikaus S, et al
    Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.
    PLoS One. 2022;17:e0262770.
    PubMed     Abstract available

  21. MCBRIDE CM, Campbell GP, Zhao J, Pentz RD, et al
    Applying citizen science to engage families affected by ovarian cancer in developing genetic service outreach strategies.
    PLoS One. 2022;17:e0262575.
    PubMed     Abstract available

  22. RUDD ML, Hansen NF, Zhang X, Urick ME, et al
    KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
    PLoS One. 2022;17:e0251286.
    PubMed     Abstract available

  23. JUMAAH AS, Al-Haddad HS, McAllister KA, Yasseen AA, et al
    The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0263585.
    PubMed     Abstract available

  24. ELSHAMI M, Tuffaha A, Yaseen A, Alser M, et al
    Awareness of ovarian cancer risk and protective factors: A national cross-sectional study from Palestine.
    PLoS One. 2022;17:e0265452.
    PubMed     Abstract available

  25. PETROCCHI S, Ongaro G, Calvello M, Feroce I, et al
    A randomized controlled trial comparing self-referred message to family-referred message promoting men's adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol.
    PLoS One. 2022;17:e0266327.
    PubMed     Abstract available

  26. ANNONI AM, Longhini C
    Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.
    PLoS One. 2022;17:e0265387.
    PubMed     Abstract available

  27. DING Y, Oliveira-Ferrer L, Vettorazzi E, Legler K, et al
    VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients.
    PLoS One. 2022;17:e0269680.
    PubMed     Abstract available

  28. HAZAMA Y, Tsujioka T, Kitanaka A, Tohyama K, et al
    Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
    PLoS One. 2022;17:e0271245.
    PubMed     Abstract available

  29. DANSONKA-MIESZKOWSKA A, Szafron LA, Kulesza M, Stachurska A, et al
    PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients.
    PLoS One. 2022;17:e0271539.
    PubMed     Abstract available

  30. ALI FT, Soliman RM, Hassan NS, Ibrahim AM, et al
    Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer.
    PLoS One. 2022;17:e0272308.
    PubMed     Abstract available

  31. SRIRAMKUMAR S, Metcalfe TX, Lai T, Zong X, et al
    Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
    PLoS One. 2022;17:e0271584.
    PubMed     Abstract available

  32. HIEPP L, Mayr D, Gartner K, Schmoeckel E, et al
    Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas.
    PLoS One. 2022;17:e0271630.
    PubMed     Abstract available

  33. LIU Y, Liu Q, Jiang X
    Bibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors.
    PLoS One. 2022;17:e0274802.
    PubMed     Abstract available

  34. HEEMSKERK-GERRITSEN BAM, Hollestelle A, van Asperen CJ, van den Beek I, et al
    Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
    PLoS One. 2022;17:e0275015.
    PubMed     Abstract available

  35. SCICCHITANO S, Montalcini Y, Lucchino V, Melocchi V, et al
    Enhanced ZNF521 expression induces an aggressive phenotype in human ovarian carcinoma cell lines.
    PLoS One. 2022;17:e0274785.
    PubMed     Abstract available

  36. DING N, Zhan J, Shi Y, Qiao T, et al
    Obesity in children and adolescents and the risk of ovarian cancer: A systematic review and dose‒response meta-analysis.
    PLoS One. 2022;17:e0278050.
    PubMed     Abstract available

  37. GONZALEZ-BOSQUET J, Weroha SJ, Bakkum-Gamez JN, Weaver AL, et al
    ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
    PLoS One. 2022;17:e0278408.
    PubMed     Abstract available

  38. DING H, He C, Tong Y, Fang Q, et al
    Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    PLoS One. 2022;17:e0279286.
    PubMed     Abstract available

  39. Expression of Concern: The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.
    PLoS One. 2022;17:e0279960.

    January 2021
  40. SATPATHY S, Patra A, Hussain MD, Kazi M, et al
    A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells.
    PLoS One. 2021;16:e0240068.
    PubMed     Abstract available

  41. MOUSTAFA D, Elwahed MRA, Elsaid HH, Parvin JD, et al
    Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    PLoS One. 2021;16:e0235025.
    PubMed     Abstract available

  42. YUK JS, Lee B, Kim K, Kim MH, et al
    Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
    PLoS One. 2021;16:e0250723.
    PubMed     Abstract available

  43. ZHANG R, Yang X, Roque DM, Li C, et al
    A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
    PLoS One. 2021;16:e0240145.
    PubMed     Abstract available

  44. ZHANG L, Hu C, Huang Z, Li Z, et al
    In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis.
    PLoS One. 2021;16:e0250717.
    PubMed     Abstract available

  45. TOKUNAGA H, Iida K, Hozawa A, Ogishima S, et al
    Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    PLoS One. 2021;16:e0236907.
    PubMed     Abstract available

  46. PRAHM KP, Hogdall CK, Karlsen MA, Christensen IJ, et al
    MicroRNA characteristics in epithelial ovarian cancer.
    PLoS One. 2021;16:e0252401.
    PubMed     Abstract available

  47. WALSH CS, Kamrava M, Rogatko A, Kim S, et al
    Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
    PLoS One. 2021;16:e0252665.
    PubMed     Abstract available

  48. OYAMA Y, Shigeta S, Tokunaga H, Tsuji K, et al
    CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
    PLoS One. 2021;16:e0251079.
    PubMed     Abstract available

  49. GUI T, Yao C, Jia B, Shen K, et al
    Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
    PLoS One. 2021;16:e0253136.
    PubMed     Abstract available

  50. LOPACINSKA-JORGENSEN J, Oliveira DVNP, Wayne Novotny G, Hogdall CK, et al
    Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    PLoS One. 2021;16:e0255142.
    PubMed     Abstract available

  51. PARIS EA, Bahr JM, Bitterman P, Basu S, et al
    Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer.
    PLoS One. 2021;16:e0255007.
    PubMed     Abstract available

  52. WANG H, Ye F, Zhou C, Cheng Q, et al
    High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
    PLoS One. 2021;16:e0245733.
    PubMed     Abstract available

  53. ALKHARUSI A, AlMuslahi A, AlBalushi N, AlAjmi R, et al
    Connections between prolactin and ovarian cancer.
    PLoS One. 2021;16:e0255701.
    PubMed     Abstract available

  54. CIRILLO PDR, Margiotti K, Fabiani M, Barros-Filho MC, et al
    Multi-analytical test based on serum miRNAs and proteins quantification for ovarian cancer early detection.
    PLoS One. 2021;16:e0255804.
    PubMed     Abstract available

  55. STEFANOU DT, Bamias A, Episkopou H, Kyrtopoulos SA, et al
    Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer.
    PLoS One. 2021;16:e0256051.
    PubMed     Abstract available

  56. MCCORKLE JR, Gorski JW, Liu J, Riggs MB, et al
    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
    PLoS One. 2021;16:e0254205.
    PubMed     Abstract available

  57. JAREID M, Snapkov I, Holden M, Busund LR, et al
    The blood transcriptome prior to ovarian cancer diagnosis: A case-control study in the NOWAC postgenome cohort.
    PLoS One. 2021;16:e0256442.
    PubMed     Abstract available

  58. NAPOLI E, Bonsdorff TB, Jorstad IS, Bruland OS, et al
    Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use.
    PLoS One. 2021;16:e0248133.
    PubMed     Abstract available

  59. HANNA DH, R Saad G
    Induction of mitochondria mediated apoptosis in human ovarian cancer cells by folic acid coated tin oxide nanoparticles.
    PLoS One. 2021;16:e0258115.
    PubMed     Abstract available

  60. HO PJ, Yeoh YS, Miao H, Lim SH, et al
    Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers.
    PLoS One. 2021;16:e0250102.
    PubMed     Abstract available

  61. MIMOUN C, Paoletti X, Gaillard T, Crestani A, et al
    Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN group.
    PLoS One. 2021;16:e0258783.
    PubMed     Abstract available

  62. ANCHOORI RK, George L, Tseng SH, Lam B, et al
    Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
    PLoS One. 2021;16:e0256937.
    PubMed     Abstract available

  63. SAAVALAINEN L, Lassus H, But A, Gissler M, et al
    Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study.
    PLoS One. 2021;16:e0253270.
    PubMed     Abstract available

  64. KAUR P, Nagar S, Bhagwat M, Uddin M, et al
    Activated heme synthesis regulates glycolysis and oxidative metabolism in breast and ovarian cancer cells.
    PLoS One. 2021;16:e0260400.
    PubMed     Abstract available

  65. WONG DH, Mardock AL, Manrriquez EN, Lai TS, et al
    Trends in extent of surgical cytoreduction for patients with ovarian cancer.
    PLoS One. 2021;16:e0260255.
    PubMed     Abstract available

  66. SAEED-VAFA D, Marchion DC, McCarthy SM, Hakam A, et al
    Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes.
    PLoS One. 2021;16:e0256615.
    PubMed     Abstract available

  67. GRESSEL GM, Usyk M, Frimer M, Kuo DYS, et al
    Characterization of the endometrial, cervicovaginal and anorectal microbiota in post-menopausal women with endometrioid and serous endometrial cancers.
    PLoS One. 2021;16:e0259188.
    PubMed     Abstract available

    January 2020
  68. FADDA M, Chappuis PO, Katapodi MC, Pagani O, et al
    Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    PLoS One. 2020;15:e0240054.
    PubMed     Abstract available

  69. SAGLAM O, Tang Z, Tang G, Medeiros LJ, et al
    KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
    PLoS One. 2020;15:e0238477.
    PubMed     Abstract available

  70. SOPO M, Sallinen H, Hamalainen K, Kivela A, et al
    High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    PLoS One. 2020;15:e0241484.
    PubMed     Abstract available

  71. ESTERMANN M, Huang YL, Septiadi D, Ritz D, et al
    Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion.
    PLoS One. 2020;15:e0241500.
    PubMed     Abstract available

  72. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2020;15:e0243944.
    PubMed     Abstract available

  73. LEANDERSSON P, Akesson A, Hedenfalk I, Malander S, et al
    A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    PLoS One. 2020;15:e0240418.
    PubMed     Abstract available

  74. WANG Y, Tao VL, Shin CY, Salamanca C, et al
    Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line.
    PLoS One. 2020;15:e0240412.
    PubMed     Abstract available

  75. PATRA B, Lateef MA, Brodeur MN, Fleury H, et al
    Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems.
    PLoS One. 2020;15:e0244549.
    PubMed     Abstract available

  76. BATES M, Spillane CD, Gallagher MF, McCann A, et al
    The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    PLoS One. 2020;15:e0243715.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.